Dyson, Jessica K.

Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team

Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., Aslam, T., Patanwala, I., Gaggar, S., Cole, M., et al. (2014) · Journal of Hepatology

Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and Treatment

Cited by 603

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines

Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 362

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis

Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 284

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

Corpechot, C., Carrat, F., Gaouar, F., Chau, F., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Schramm, C., Pares, A., et al. (2022) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 128

Novel therapeutic targets in primary biliary cirrhosis

Dyson, J. K., Hirschfield, G. M., Adams, D. H., Beuers, U., Mann, D. A., Lindor, K. D., & Jones, D. E. J. (2015) · Nature Reviews Gastroenterology & Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 120

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

Corpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 94

Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score

Hegade, V. S., Khanna, A., Walker, L. J., Wong, L.-L., Dyson, J. K., & Jones, D. E. J. (2016) · Digestive Diseases and Sciences

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 86

The new epidemiology of primary biliary cirrhosis

Griffiths, L., Dyson, J., & Jones, D. (2014) · Seminars in Liver Disease

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 79

The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis

Dyson, J. K., Wilkinson, N., Jopson, L., Mells, G., Bathgate, A., Heneghan, M. A., Neuberger, J., Hirschfield, G. M., Ducker, S. J., The UK‐PBC Consortium, et al. (2016) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 78

Unmet clinical need in autoimmune liver diseases

Dyson, J. K., Webb, G., Hirschfield, G. M., Lohse, A., Beuers, U., Lindor, K., & Jones, D. E. J. (2015) · Journal of Hepatology

Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases

Cited by 66

The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis

Barron‐Millar, B., Ogle, L., Mells, G., Flack, S., Badrock, J., Sandford, R., Kirby, J., Palmer, J., Jopson, L., Brain, J., et al. (2021) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 45

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 38

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis

Martinez-Gili, L., Pechlivanis, A., McDonald, J. A. K., Begum, S., Badrock, J., Dyson, J. K., Jones, R., Hirschfield, G., Ryder, S. D., Sandford, R., et al. (2023) · Gut Microbes

Liver Diseases and ImmunityGut microbiota and health

Cited by 32

Early Molecular Stratification of High-risk Primary Biliary Cholangitis

Hardie, C., Green, K., Jopson, L., Millar, B., Innes, B., Pagan, S., Tiniakos, D., Dyson, J., Haniffa, M., Bigley, V., et al. (2016) · EBioMedicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 32

The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study

Jones, D. E. J., Wetten, A., Barron-Millar, B., Ogle, L., Mells, G., Flack, S., Sandford, R., Kirby, J., Palmer, J., Brotherston, S., et al. (2022) · eBioMedicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 22

Anti-Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct-Ligated Mice

Gee, L. M. V., Barron-Millar, B., Leslie, J., Richardson, C., Zaki, M. Y. W., Luli, S., Burgoyne, R. A., Cameron, R. I. T., Smith, G. R., Brain, J. G., et al. (2023) · The American Journal of Pathology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 18

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid

Dunn, S., Evans, L., Kennedy, C., Wafer, R., Moody, S., Wolstenhulme, F., Burton, E., Konkoth, A. B., Fisher, H., Chadwick, T., et al. (2026) · BMJ Open

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 0